Pacific Edge in holding mode as US Medicare decision nears

Pacific Edge in holding mode as US Medicare decision nears
Total laboratory use of Pacific Edge's Cxbladder tests in the US rose in the 2024 financial year but the growth rate slowed in the second half as the company reduced its sales team. (Image: Thinkstock)
Greg Hurrell
Pacific Edge says the 2024 finance year has been one of two halves, as it quickly switched from growth to capital preservation.That sudden change of focus came from a major setback with the possible loss of access to the US Medicare system which has been its largest customer.The company reported a loss of $29.5 million for the March 31 financial year, 9.5% bigger than 2023’s net loss, amid that slowing growth.MedicareThe company said it was prepared for all outcomes as it waited to see whether it would hang on to its Medicare deal, which...

More Markets

Forsyth Barr shifts Turners Automotive to neutral
Markets

Forsyth Barr shifts Turners Automotive to neutral

The company has delivered five consecutive years of record earnings.

Vital board backs Tait takeover
Markets

Vital board backs Tait takeover

Vital’s board has unanimously recommended that shareholders and option holders accept a full takeover offer from Tait Communications, despite their view that it undervalues the company.In May, Vital shares rallied after it disclosed that Tait, a Christchurch-based critical commun...

Listed property firms welcome ‘Investment Boost'
Property

Listed property firms welcome ‘Investment Boost'

The tax policy could translate into millions in extra cash.

Drury’s ASX stag, MetroGlass’s new owner, and more
Markets Small Cap Wrap

Drury’s ASX stag, MetroGlass’s new owner, and more

Rod Drury goes ‘pre-revenue’ again, plus small cap news from NZ.